TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04283708

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Submental liposuction
Description: Advancement Genioplasty With Submental Liposuction
Study: NCT02409095

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: DTP-HB-Hib vaccine
Description: Diphtheria, Tetanus, Pertussis, Hepatitis-B and Haemophilus influenzae type-B conjugate vaccine (DTP-HB-Hib) has been developed and manufactured by SIIL. The vaccine is pre-qualified by WHO and licensed by the Indian regulatory authority for immunization in children to protect them against above five diseases.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: DTP-HB-Hib vaccine
Description: Diphtheria, Tetanus, Pertussis, Hepatitis-B and Haemophilus influenzae type-B conjugate vaccine (DTP-HB-Hib) has been developed and manufactured by SIIL. The vaccine is pre-qualified by WHO and licensed by the Indian regulatory authority for immunization in children to protect them against above five diseases.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Disposable Syringe Jet Injector (DSJI)
Description: Stratis is a needle free injection device manufactured by Pharamjet Inc. and licensed in USA.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Needle & Syringe
Description: The conventional needle syringe that is routinely used for vaccination.
Study: NCT00981539

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: enema
Description: pre operative rectal enema~one adult bottle to be used rectally the night before surgery
Study: NCT01234883

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: multiple electrolyte solution
Description: IV multiple electrolyte solution dosed as clinically indicated for rehydration
Study: NCT02328937

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: lotrafilcon B
Study: NCT01234883

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: saline
Description: IV solutions dosed as clinically indicated for rehydration
Study: NCT02342990

Intervention type: OTHER
Group type: OTHER
Intervention: Cluster B CogMed: an home-based and computer-based solution to improve working memory deficit
Description: CogMed: an home-based and computer-based solution to improve working memory deficit

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cluster B CogMed: an home-based and computer-based solution to improve working memory deficit
Description: CogMed: an home-based and computer-based solution to improve working memory deficit

Intervention type: OTHER
Group type: OTHER
Intervention: Cluster A No training. Delay start of CogMed
Description: No training will be provided after T1 time point. Cluster A will start the CogMed training after the assessment at the T2 time point
Study: NCT01481688

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise
Description: Exercise During Dialysis Patients will be asked to carry out cycling exercise for 60 minutes during the third quarter of their routine haemodialysis session. Exercise can be carried out in ten minute bouts with several minutes rest between bouts.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Extra time
Description: An extra 30 minutes will be added to the currently prescribed treatment time of each patient.
Study: NCT03193463

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Topotecan (<=8cc)
Description: In predominantly enhancing mass with a volume of 8 cc or less of topotecan administered

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Topotecan (>8cc)
Description: In predominantly enhancing mass with a volume of \> 8 cc of topotecan administered. Initial rate is 0.834ml/hour with an increase to 1.668 ml/hour at the second infusion

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cleveland Multiport Catheter
Description: an investigational device, will be used to deliver the topotecan

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cleveland Multiport Catheter
Description: an investigational device, will be used to deliver the topotecan

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cleveland Multiport Catheter
Description: an investigational device, will be used to deliver the topotecan

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Imaging (MRI)
Description: to monitor the infusion of topotecan into the tumor

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Imaging (MRI)
Description: to monitor the infusion of topotecan into the tumor

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Imaging (MRI)
Description: to monitor the infusion of topotecan into the tumor

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lower Does Topotecan
Description: Rate for non-enhancing tumors has an initial dose of 0.29ml/hour
Study: NCT04339660

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: UC-MSCs
Description: 1\*10E6 UC-MSCs /kg body weight suspended in 100mL saline

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 100mL saline intravenously
Study: NCT02328937

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: comfilcon A

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: comfilcon A

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: comfilcon A
Study: NCT02429479

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Making Your Wishes Known
Description: Making Your Wishes Known provides tailored education, values clarification exercises, and a sophisticated decision aid that translates an individual's goals and preferences into a specific medical plan that can be implemented by a healthcare team.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Making Your Wishes Known
Description: Making Your Wishes Known provides tailored education, values clarification exercises, and a sophisticated decision aid that translates an individual's goals and preferences into a specific medical plan that can be implemented by a healthcare team.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard advance care planning
Description: This is a online simple living will form.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard advance care planning
Description: This is a online simple living will form.
Study: NCT04412083

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: PPA Tele-Savvy Pilot Intervention
Description: We will engage PPA caregivers in the process of adapting the existing Tele-Savvy program to fit their needs and then pilot test the adapted PPA Tele-Savvy program.
Study: NCT01543022

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Symphony
Description: The Symphony system has been developed for superficial implantation without the need to enter the chest. It allows for complete patient mobility and provides counter pulsation therapy for up to 30 days in hospitalized patients.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: The operative approach is limited to an infraclavicular incision similar to that used for placement of a pacemaker
Description: The vascular graft is surgically attached (anastomosed) to the subclavian artery. The symphony device is implanted into a pocket below the pectoralis muscle on the anterior chest and attached to the graft. The driveline is tunneled out through the skin and attached to the drive console.
Study: NCT00787306

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Active risk factor surveillance
Description: Cardiovascular risk status assessment followed by active surveillance and physician review where risk factor control is suboptimal

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Active risk factor surveillance
Description: Cardiovascular risk status assessment followed by active surveillance and physician review where risk factor control is suboptimal
Study: NCT03405077

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: IPT Online Training
Description: First, college mental health clinicians will complete baseline online questionnaires and deliver their usual treatment to 1 or 2 clients with symptoms of eating disorders. Then, they will complete the guided online training program and post-training assessments. Next, they will treat 1 or 2 different clients with eating disorders and complete post-training assessments. As part of the baseline and post-training assessments, clinicians will complete a telephone-based simulation assessment with staff raters, in which the investigators will recreate a client session and rate how well the clinicians adhere to IPT in treating the simulated client. The guided on-line training program will ultimately be compared to the gold standard training.
Study: NCT03486483

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise
Description: Intervention included 18 slackline rehabilitation sessions for 6 weeks: 3 sessions per week on non-consecutive days, 30 min each one.
Study: NCT02615509

Intervention type: RADIATION
Group type: OTHER
Intervention: Imaging on experimental tomo device
Description: The system used for imaging in the experimental arm is the Philips MicroDose tomography system. The system used for imaging in the active comparator is a standard FFDM system
Study: NCT01526837

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Avastin
Description: Topical Avastin plus Collagen Sponge placed in surgical cavity after resection of recurrent brain tumor. Dosing range: 0.25 mg/ml - 25 mg/ml.
Study: NCT02738645

Intervention type: OTHER
Intervention: pneumonia
Study: NCT03002142

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Hearing aids
Description: Phonak Audéo B-R (Target V 5.0)

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Phonak Audéo B-R (Target V 5.0) without amplification
Study: NCT01717079

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Sham rTMS
Description: 120 pulses 0.2Hz

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: rTMS
Description: 120 pulses 0.2Hz
Study: NCT04118413

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: erector spinae plane block
Description: Erector espine plane block will be administrated bilaterally to this group at low thoracic level (Th11).
Study: NCT00193479

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Cyclophosphamide

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mitoxantrone
Description: Mitoxantrone

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vincristine
Description: Vincristine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone
Description: Prednisone

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: Rituximab
Study: NCT01416857

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: RDDT
Study: NCT04575181

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NNC0268-0965
Description: For subcutaneous (s.c., under the skin) injection once daily for 26 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Insulin glargine
Description: For s.c. injection once daily for 26 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo (NNC0268-0965)
Description: For s.c. injection once daily for 26 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo (insulin glargine)
Description: For s.c. injection once daily for 26 weeks
Study: NCT03321110

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo (dextrin)

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Coenzyme Q10
Description: 150 mg or 300 mg
Study: NCT02021110

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ursodeoxycholic Acid
Description: The intervention group will receive 15-20mg/kg/day UDCA for 24 weeks
Study: NCT01727362

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Usual care + acupuncture
Description: Patients of this group receive a semi-standardized acupuncture treatment over 6 month in addition to usual care

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Usual care
Description: Patients of this group receive usual care only
Study: NCT03983434

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Inulin
Description: Inulin ingestion is not being used to diagnose, treat, or prevent IBS. Inulin is being used to study an individual's ability to ferment dietary fiber.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Inulin
Description: Inulin ingestion is not being used to diagnose, treat, or prevent IBS. Inulin is being used to study an individual's ability to ferment dietary fiber.
Study: NCT03321110

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Coenzyme Q10
Description: 150 mg or 300 mg
Study: NCT03267446

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 3D Doppler Ultrasound
Description: 3D volumes will be obtained in automatic sweeps using a motorized curved-array transducer while the women held their breath. In order to interpret the data consistently, the settings of power, On Voluson E10; GE Medical Systems)
Study: NCT04329572

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydroxychloroquine Sulfate
Description: All patients included in the study will receive HCQ (400 mg BID on D1 and 400 mg/day on D2 to D5) for 5 days.
Study: NCT03983434

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Inulin
Description: Inulin ingestion is not being used to diagnose, treat, or prevent IBS. Inulin is being used to study an individual's ability to ferment dietary fiber.
Study: NCT01476800

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: YM178 OCAS
Description: oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: YM178 OCAS
Description: oral

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ketoconazole
Description: oral
Study: NCT03256357

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Constraint-induced movement therapy
Description: In a 2-week day camp model children receive constraint- induced movement therapy for six hours a day, for 9 out of 11 consecutive days. All children wear a tailor made hand splint on the unaffected upper limb for 6 hours per day while performing unimanual exercises individually or in a group based on shaping and repetitive practice.

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Constraint-induced movement therapy
Description: In a 2-week day camp model children receive constraint- induced movement therapy for six hours a day, for 9 out of 11 consecutive days. All children wear a tailor made hand splint on the unaffected upper limb for 6 hours per day while performing unimanual exercises individually or in a group based on shaping and repetitive practice.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Action observation training
Description: Action observation training consists of 15 sessions of 1 hour. Children watch 3 minute video clips of unimanual goal-directed actions followed by 3 minutes of execution of the actions.

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo observation training
Description: Placebo observation training consists of 15 sessions of 1 hour. Children perform the same actions as the AOT training after watching computer games without biological movements.
Study: NCT03344146

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Medication intake reminders
Description: Acoustic and visual alarm at predefined DOAC-intake timepoints.

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Medication intake reminders
Description: Acoustic and visual alarm at predefined DOAC-intake timepoints.

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Pillbox use and counselling
Description: All patients will be counselled based on their previous electronically recorded adherence data and will be given a multicompartment pillbox für daily use

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Pillbox use and counselling
Description: All patients will be counselled based on their previous electronically recorded adherence data and will be given a multicompartment pillbox für daily use
Study: NCT05485233

Intervention type: DEVICE
Intervention: REDSCAR App
Description: Patients will be discharged after surgery at the time it is considered by the responsible physician. Prior to discharge, patients taking part in the study will follow the same protocol as any other patient treated in our institution. Written consent will be signed after complete explanation of the study protocol by the researcher at this moment. The patient will download the RedScar© application and the researcher will explain how it works and how to answer all the questions about the wound (redness, pain).~At day 3th and 10th after surgery, each patient will upload an image of the surgical wound via RedScar© aplication using their own smartphone device. RedScar© aplication will evaluate the risk of complications of the surgical wound and will assign patients to 2 different groups: potential complications requiring new consultation or satisfactory evolution and discharge.
Study: NCT01664507

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: conventional dose epinephrine
Description: conventional dose epinephrine : 0.5mg/kg + 0.9% normal saline

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: low dose epinephrine
Description: low dose epineprhine : 0.1mg/kg + 0.9% normal saline
Study: NCT01884545

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Health coaching
Description: Telephonic health coaching sessions with a trained certified health coach for a period of 6 months (total of 10 biweekly calls).

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Health coaching
Description: Telephonic health coaching sessions with a trained certified health coach for a period of 6 months (total of 10 biweekly calls).

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: Genetic risk counseling
Description: In addition to the SRA subjects will receive genetic risk counseling at the risk counseling visit with a clinic provider. Genetic test results for CHD (rs10757274) and T2D (rs7903146, rs1801282, rs5219) risk variants will be incorporated into the risk profile reviewed with subjects.

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: Genetic risk counseling
Description: In addition to the SRA subjects will receive genetic risk counseling at the risk counseling visit with a clinic provider. Genetic test results for CHD (rs10757274) and T2D (rs7903146, rs1801282, rs5219) risk variants will be incorporated into the risk profile reviewed with subjects.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Standard risk assessment
Description: Standard risk assessment for coronary heart disease (CHD) and type 2 diabetes (T2D). Standard risk factors are reviewed by a provider at a risk counseling visit with the subject.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Standard risk assessment
Description: Standard risk assessment for coronary heart disease (CHD) and type 2 diabetes (T2D). Standard risk factors are reviewed by a provider at a risk counseling visit with the subject.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Standard risk assessment
Description: Standard risk assessment for coronary heart disease (CHD) and type 2 diabetes (T2D). Standard risk factors are reviewed by a provider at a risk counseling visit with the subject.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard risk assessment
Description: Standard risk assessment for coronary heart disease (CHD) and type 2 diabetes (T2D). Standard risk factors are reviewed by a provider at a risk counseling visit with the subject.
Study: NCT04513171

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Y-shape pegylated somatropin
Description: Y-shape pegylated somatropin 100μg/kg, subcutaneous injection, Once weekly.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Y-shape pegylated somatropin
Description: Y-shape pegylated somatropin 120μg/kg, subcutaneous injection, Once weekly.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Y-shape pegylated somatropin
Description: Y-shape pegylated somatropin 140μg/kg, subcutaneous injection, Once weekly.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Norditropin®
Description: Norditropin 245μg/kg/week, subcutaneous injection, Once daily.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Y-shape pegylated somatropin
Description: Y-shape pegylated somatropin 140μg/kg, subcutaneous injection, Once weekly.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Norditropin
Description: Norditropin 245μg/kg/week, subcutaneous injection, Once daily.
Study: NCT02542592

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Methylprednisolone
Description: Comparison of preoperative single high dose of Methylprednisolone 125 mg iv. and isotonic Sodium Chloride (placebo)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Isotonic Sodium Chloride
Description: Placebo
Study: NCT04329572

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azithromycin Tablets
Description: All patients included in the study will receive AZT 500 mg per day for 5 days.
Study: NCT02497846

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: TEOSYAL® PureSense Redensity [I]/MicronJet®
Description: According the instruction of use, 3 injections of TEOSYAL® PureSense Redensity \[I\]will be performed all the 3 weeks. The used needle will be the MicronJet® microneedles for product injection. And the last visit (of control) will be performed 3 weeks after the last injection.
Study: NCT02294851

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-986168

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: BMS-986168 Placebo